GC Pharma, IDRI and MIBR Bringing Together to Develop
Innovative Vaccines
YONGIN, South Korea,
May 20, 2018 /PRNewswire/ -- GC Pharma (formerly known as
Green Cross Corporation) (KRX: 006280), a South Korean
biopharmaceutical company, today announced the establishment of
Curevo Inc. ("Curevo"). The newly established Seattle-based company's goal is to support GC
Pharma's vaccine development activities.
GC Pharma builds a strategic collaboration and partnership with
global health organizations IDRI (Infectious Disease Research
Institute) and MIBR (Mogam Institute for Biomedical Research) to
form the new company.
Curevo represents an important next step in GC Pharma's vaccine
business. The new company will bring together GC Pharma's
commercial scale vaccine development expertise and deep
understanding of protein science with IDRI and MIBR's world class
scientific expertise in vaccine, adjuvant and formulation
development. Initial work will centre on advancing an innovative
vaccine candidate against shingles to clinical stage.
"Establishing Curevo signals a crucial step forward in GC
Pharma's long-standing dedication to prevent potentially serious
diseases," said EC Huh, Ph. D. President of GC Pharma. "This
exciting collaboration will increase the possibilities for
immune-compromised populations to have better options."
"The bottom line is that this new collaboration will take
advantage of the combined strength of these three organizations to
more rapidly develop infectious disease vaccines and bring them to
market," said Steve Reed, Ph. D.,
IDRI's President, CEO and Founder.
"MIBR scientists have been focusing on discovering novel cancer
therapeutics and vaccines. Curevo creates an excellent conduit to
achieve those goals by joining forces with GC Pharma and IDRI,"
said Senyon Teddy Choe, Ph. D.,
MIBR's President and Director.
Corey Casper, M. D., M. P. H.
IDRI's Chief Medical Officer will lead the shingles project of the
new company. Dr. Casper has more than 20 years of experience in
designing, growing and sustaining internationally recognized
programs in infection-related cancer, HIV, infection control and
global oncology. He also has extensive experience leading
multi-phased international clinical trials.
About GC Pharma
GC Pharma (formerly known as Green Cross Corporation) is a
biopharmaceutical company that delivers life-saving and
life-sustaining protein therapeutics and vaccines. Headquartered in
South Korea, GC Pharma is the
largest plasma protein product manufacturer in Asia and has been dedicated to quality
healthcare solutions more than half a century. Green Cross
Corporation updates its corporate brand as GC Pharma in early 2018.
Green Cross Corporation remains the company's registered, legal
name. For more information, please visit www.globalgreencross.com
About IDRI
As a non-profit global health organization, IDRI (Infectious
Disease Research Institute) takes a comprehensive approach to
combat infectious diseases, combining the high-quality science of a
research organization with the product development capabilities of
a biotech company to create new diagnostics, drugs and vaccines.
Founded in 1993, IDRI has 125 employees headquartered in
Seattle with nearly 100
partners/collaborators around the world. For more information,
visit www.idri.org.
About MIBR
As a non-profit global research organization, MIBR (Mogam
Institute for Biomedical Research) is engaged in basic drug
discovery research to combat infectious diseases, cancer, and rare
diseases. Founded in 1984, MIBR is headquartered in southern
Seoul with a number of research
collaborations ongoing with GC Pharma. For more information, visit
www.mogam.re.kr.
This release includes forward-looking statements, which
express the current beliefs and expectations of GC Pharma's
management. Such statements speak only as of the date on which they
are made and the Company undertakes no obligation to update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
Photo - https://mma.prnewswire.com/media/693516/Curevo.jpg